Thrombosis Prevention After Total Hip Arthroplasty

Colwell Jr., Clifford W.; Froimson, Mark I.; Mont, Michael A.; Ritter, Merrill A.; Trousdale, Robert T.; Buehler, Knute C.; Spitzer, Andrew; Donaldson, Thomas K.; Padgett, Douglas E.
March 2010
Journal of Bone & Joint Surgery, American Volume;Mar2010, Vol. 92-A Issue 3, p527
Academic Journal
Background: Thromboembolic disease is a common complication of total hip arthroplasty. The purpose of this study was to compare a new mobile compression device with low-molecular-weight heparin with regard to their safety and effectiveness for the prevention of venous thromboembolic disease. Methods: Patients who had a total hip arthroplasty were randomized to receive prophylaxis with a mobile compression device or low-molecular-weight heparin for ten days. Use of the compression device began intraoperatively, and the patients in this group could receive 81 mg of aspirin daily after the surgery. The first injection of the low-molecular-weight heparin began between twelve and twenty-four hours after the surgery. After ten to twelve days, all patients underwent bilateral lower-extremity duplex ultrasonography to screen for deep venous thrombi in the calf and thigh. Any clinical symptoms of pulmonary embolism were evaluated with spiral computed tomography lung scans. Bleeding events and utilization of (i.e., compliance with) prophylactic treatment in both groups were documented. Clinical evaluation to look for evidence of deep venous thrombi and pulmonary emboli was performed at twelve weeks postoperatively. Results: Four hundred and ten patients (414 hips) were randomized; 392 of these patients (395 of the hips) were evaluable with regard to the safety of the intervention and 386 patients (389 hips) were evaluable with regard to its efficacy. Demographics were similar clinically between the groups. The rate of major bleeding events was 0% in the compression group and 6% in the low-molecular-weight heparin group. The rates of distal and proximal deep venous thrombosis were 3% and 2%, respectively, in the compression group compared with 3% and 1% in the heparin group. The rates of pulmonary embolism were 1% in the compression group and 1% in the heparin group, and there were no fatal pulmonary emboli. Within the twelve-week follow-up period, two events (one deep venous thrombosis and one pulmonary embolus) occurred in one patient in the compression group following negative findings on duplex ultrasonography on the twelfth postoperative day. There was no difference between the groups with regard to the prevalence of venous thromboembolism. Conclusions: When compared with low-molecular-weight heparin, use of the mobile compression device for prophylaxis against venous thromboembolic events following total hip arthroplasty resulted in a significant decrease in major bleeding events.


Related Articles

  • New Anticoagulants for the Prevention of Thromboembolism. Lepic, Kylie; Crowther, Mark // Current Pharmaceutical Design;10/21/2010, Vol. 16 Issue 31, p3472 

    No abstract available.

  • THROMBOPROPHYLAXIS AND DEATH AFTER TOTAL HIP REPLACEMENT. Force, Rex // Journal of Family Practice;Mar1997, Vol. 44 Issue 3, p248 

    The article examines the risk of fatal pulmonary embolism (PE) and total mortality after total hip replacement (THR). To find all the relevant literature that discussed fatal PE and total mortality in patients receiving THR, a MEDLINE search was conducted from 1966 to 1995. The types of...

  • Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. Granziera, Serena; Cohen, Alexander T.; Anderson, David R.; Dunbar, Michael J.; Kahn, Susan R. // Annals of Internal Medicine;10/1/2013, Vol. 159 Issue 7, p502 

    A letter to the editor is presented in response to the article "Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: A randomized trial" by D.R. Anderson and friends in a 2013 issue along with a response by authors to the same.

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS29 

    Presents an abstract of the research manuscript `Preoperative enoxaparin is more effective than postoperative enoxaparin in the prevention of deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR): A pooled analysis,' by K.A. Valentine, R.D. Hull et al from the University...

  • CME quiz.  // Orthopedics;Nov2003, Vol. 26 Issue 11, p1162 

    Presents a quiz concerning the dosing and timing of low-molecular-heparin thromboprophylaxis in total hip arthroplasty.

  • Inflammatory pseudotumor of the hip: a complication of arthroplasty to be recognized by the radiologist. de Melo Santos Vilas Boas, Raquel; Andrade Madeira, Ivana; Abuhid Lopes, Alexia; Barreto Paiva, Edson; Soares Rodrigues, AndrĂ© // Radiologia Brasileira;set/out2015, Vol. 48 Issue 5, p314 

    Soft tissue complications following hip arthroplasty may occur either in cases of total hip arthroplasty or in hip resurfacing, a technique that has become popular in cases involving young patients. Both orthopedic and radiological literatures are now calling attention to these symptomatic...

  • Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. Leyvraz, P.F.; Bachmann, F.; Hoek, J.; Buller, H.R.; Postel, M.; Samama, M.; Vandenbroek, M.D. // BMJ: British Medical Journal (International Edition);9/7/91, Vol. 303 Issue 6802, p543 

    Examines the effectiveness of two subcutaneous prophylactic regimens for postoperative deep vein thrombosis in patients undergoing total hip replacement in Europe. Comparison between low molecular wight heparin and unfractioned heparin; Application of prophylactic measures in hip surgery; Use...

  • The risk of venous clots and heparin therapy. Ferraro, Julia // RN;Dec96, Vol. 59 Issue 12, p16 

    Shows the effectiveness of heparin in controlling deep vein thromboembolism for patients who had total hip replacement. Comparison of this therapy from placebos; Cost effectiveness of the therapy.

  • Can a new design of pneumatic compression device reduce variations in delivered therapy for the mechanical prophylaxis of thromboembolic disease after total hip arthroplasty? Masri, Bassam A.; Dunlop, David J.; McEwen, James A.; Garbuz, Donald S.; Duncan, Clive P. // Canadian Journal of Surgery;Aug2004, Vol. 47 Issue 4, p263 

    Background: Compression devices have been shown to prevent thromboembolic disease, However, the pressures generated may not be the same as the ones recommended by the manufacturer. The purpose of this study is to investigate a new sequential compression device with feedback to maintain optimal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics